Too Pricey For A Patent? Glivec Rejected
Novartis’s patent application for Glivec, a blood cancer drug, was recently ruled not patentable by the Intellectual Property Appellate Board of India (IPAB) for failing to meet the requirements under section 3(d) of the Indian Patent Act, which states that…
